The lawsuit, filed June 6 on the behalf of parties that purchased Teladoc shares between October and April, accuses the company, along with CEO Jason Gorevic and CFO Mala Murthy, of downplaying competition in the mental health and chronic care business sectors, along with issuing “unrealistic” financial expectations for 2022.
The lawsuit also highlights Teladoc’s first-quarter 2022 earnings report, in which the company reported a total net loss of $6.6 billion as well as a “non-cash goodwill impairment” charge of $6.6 billion.
As a result, the plaintiff alleges that stakeholders are now suffering “significant losses and damages” and asks that Teladoc be required to pay damages sustained by the plaintiffs.
In a statement to Becker’s, a Teladoc spokesperson said that there “is no factual basis to the suit whatsoever,” and that “lawsuits like this one have become commonplace for public companies.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
